



Neurogene to Participate in Stifel 2026 Virtual CNS Forum

March 11, 2026

NEW YORK--(BUSINESS WIRE)--Mar. 11, 2026-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum.

Format: Management will participate in a fireside chat

Date: Wednesday, March 18 at 9:00 a.m. ET

A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene's website under [events](#), where a replay of the event will also be available for a limited time.

About Neurogene

Neurogene (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program, NGN-401, as a potential best-in-class, one-time treatment for Rett syndrome. For more information, visit neurogene.com or follow on [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260311342818/en/): <https://www.businesswire.com/news/home/20260311342818/en/>

Company Contact:

Mike Devine

Executive Director, Corporate Communications

michael.devine@neurogene.com

Investor Contact:

Argot Partners

Neurogene@argotpartners.com

Source: Neurogene Inc.